Circulating cytokines and angiogenic factors based signature associated with the relative dose intensity during treatment in patients with advanced hepatocellular carcinoma receiving lenvatinib

BACKGROUND: Although lenvatinib was recently approved for treatment of advanced unresectable hepatocellular carcinoma (HCC) based on the phase III REFLECT trial, no biomarkers for management of lenvatinib treatment have been established. The aim of this study is to identify predictive biomarkers for...

Descripción completa

Detalles Bibliográficos
Autores principales: Ono, Atsushi, Aikata, Hiroshi, Yamauchi, Masami, Kodama, Kenichiro, Ohishi, Waka, Kishi, Takeshi, Ohya, Kazuki, Teraoka, Yuji, Osawa, Mitsutaka, Fujino, Hatsue, Nakahara, Takashi, Murakami, Eisuke, Miki, Daiki, Kawaoka, Tomokazu, Abe-Chayama, Hiromi, Zhang, Peiyi, Liu, Songyao, Makokha, Grace Naswa, Tsuge, Masataka, Imamura, Michio, Hayes, C. Nelson, Chayama, Kazuaki
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2020
Materias:
Early Diagnosis and Therapeutic Advances for Liver Cancer: From Bench to Bedside
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7249573/
https://www.ncbi.nlm.nih.gov/pubmed/32547646
http://dx.doi.org/10.1177/1758835920922051

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7249573/
https://www.ncbi.nlm.nih.gov/pubmed/32547646
http://dx.doi.org/10.1177/1758835920922051

Ejemplares similares